

Edgar Filing: Pharma-Bio Serv, Inc. - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 29, 2018, Pharma-Bio Serv, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders. Below is a summary of the proposals and corresponding votes.

Kirk Michel and Dov Perlysky were elected as Class II directors to serve for a term until the 2021 Annual Meeting of Stockholders or until successors are duly elected and qualified. Kirk Michel and Dov Perlysky received the following votes:

Nominee	For	Withheld
Kirk Michel	13,852,866	53,000
Dov Perlysky	13,852,866	53,000

There were 4,942,634 broker non-votes on this proposal.

The ratification of the selection of Horwath Velez & Co. PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2018 received the following votes:

For	Against	Abstain
18,819,557	0	28,943

There were no broker non-votes on this proposal.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMA-BIO SERV, INC.

Date: June 29, 2018 By: /s/ Pedro J. Lasanta
Pedro J. Lasanta
Chief Financial Officer, Vice President Finance and
Administration and Secretary